DOCSLIB.ORG

Association of HLA-A*31:01 Screening with the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Popul

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Association of HLA-A*31:01 Screening with the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Popul Supplementary Online Content Mushiroda T, Takahashi Y, Onuma T, et al; GENCAT Study Group. Association of HLA- A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurol. Published online April 2, 2018. doi:10.1001/jamaneurol.2018.0278 eTable 1. Detailed Classification Criteria of Cutaneous Adverse Drug Reactions (cADRs) Used for the Review by Expert Dermatologists eTable 2. List of Drugs Prescribed Before and After HLA-A*31:01 Screening of 198 HLA-A*31:01-Positive Participants eTable 3. Details of the Review by Expert Dermatologists of Cases Initially Diagnosed as Cutaneous Adverse Drug Reactions (cADRs) According to HLA-A*31:01 Screening Results eTable 4. Comparison of the Incidences of other Adverse Events Between HLA-A*31:0- Positive and HLA-A*31:0-Negative Patients This supplementary material has been provided by the authors to give readers additional information about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 eTable 1. Detailed Classification Criteria of Cutaneous Adverse Drug Reactions (cADRS) Used for the Review by Expert Dermatologists Category of Definition of “carbamazepine- Definition of “cADRs” cADR induced cADRs” There is sufficient information to Definite cADR and can specify Definite diagnose a cADR and specify a carbamazepine as a culprit drug. culprit drug. Some information is missed, but Probable cADR and can specify the collected information is carbamazepine as a culprit drug. Probable sufficient to diagnose a cADR and specify a culprit drug. Collected information cannot Not included in the exclude the possibility of a cADR, carbamazepine-induced cADR. Possible but indicate a possibility of other skin diseases. Collected information indicates Not included in the high possibility of cADR caused carbamazepine-induced cADR. by other drugs, high possibility of Unlikely other skin diseases, or collected information are insufficient to diagnose either cADR or other skin diseases. Clinical information of cADR including 1) days from the drug start to the onset, 2) treatment, 3) clinical course, and 4) outcome. Required Photographs of a cADR information to Initial diagnosis of attended dermatologists diagnose a cADR Information of concurrent drugs (to estimate the possibility of other suspected culprit drugs) Drugs that satisfy all of the three criteria written below: 1) Drugs which was started or terminated during the carbamazepine Definition of the treatment. possibility of culprit 2) The date of cADR onset was within one week from the start of the drug other than drug. carbamazepine 3) Exclude drugs which was started during the carbamazepine treatment and continued even after the cADR disappeared. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 eTable 2. List of Drugs Prescribed Before and After HLA-A*31:01 Screening of 198 HLA-A*31:01-Positive Participants Drugs prescribed Drugs added after HLA- Number Number of patients who before the study A*31:01 screening of stopped additional patients drugs (reasons) None Carbamazepine 1 1 (other causes) None Clonazepam 3 1 (other causes) None Gabapentin 1 None Lamotrigine 1 None Levetiracetam 6 2 (other causes) None Levetiracetam + 2 Clonazepam None Levetiracetam + 1 1 (cADRs) Gabapentin None Levetiracetam + 2 Nitrazepam None Levetiracetam + 1 Phenobarbital None Levetiracetam + 2 Phenytoin None Levetiracetam + 1 Phenytoin + Lamotrigine None Phenobarbital 2 None Phenytoin 8 None Sodium valproate 42 1 (cADRs), 1 (other adverse reactions), 2 (other causes) None Sodium valproate + 1 Gabapentin None Sodium valproate + 11 Levetiracetam None Sodium valproate + 1 Levetiracetam + Clobazam None Sodium valproate + 2 Phenobarbital None Sodium valproate + 1 1 (other causes) Zonisamide + Levetiracetam None Tiapride 1 None Tramadol-acetaminophen 1 1 (other causes) None Tramadol-acetaminophen 2 + Pregabalin None Zonisamide 17 1 (cADRs) None Zonisamide + Diazepam 1 None Zonisamide + 1 Levetiracetam Clonazepam None 1 © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 Levetiracetam + None 2 Phenytoin Phenytoin + None 1 Gabapentin + Phenobarbital Sodium valproate None 2 1 (other causes) Sodium valproate + None 1 1 (other causes) Chlorpromazine Sodium valproate + None 1 Levetiracetam Sodium valproate + None 1 Zonisamide Aripiprazole Levetiracetam + 1 Phenytoin Bromazepam Phenytoin + 1 Bromazepam (dose escalation) + Sertraline Brotizolam Sodium valproate + 1 Trazodone Clonazepam Levetiracetam 1 Clonazepam + Aripiprazole 1 Biperiden + Hydroxyzine + Paliperidone Clonazepam + Olanzapine 1 Biperiden + Saikokaryukotsuborei to + Paroxetine + Chlorpromazine- promethazine- phenobarbital + Lorazepam + Flunitrazepam Clonazepam + Sodium valproate 1 Biperiden + Zopiclone + Quetiapine + Lithium Clonazepam + Amoxapine + Lithium 1 1 (other adverse Quetiapine reactions) Diazepam Sodium valproate 1 Diazepam Sodium valproate + 1 1 (other causes) Phenytoin + Phenobarbital Gabapentin Levetiracetam 1 Levetiracetam Lamotrigine 2 Levetiracetam Sodium valproate 1 Levetiracetam Topiramate 1 Levetiracetam Zonisamide 3 Levetiracetam + Topiramate 1 © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 Gabapentin Lorazepam + Sodium valproate 1 Clotiazepam Nitrazepam Zonisamide 1 1 (other adverse reactions) Paliperidone Aripiprazole + Sertraline 1 Paliperidone Blonanserin 1 Paliperidone + Sodium valproate 1 Etizolam + Promethazine + Ethyl loflazepate + Trazodone Paliperidone + Olanzapine 1 Triazolam Paroxetine + Olanzapine 1 Lorazepam Phenytoin Levetiracetam + 1 Phenytoin (dose escalation) Phenytoin Levetiracetam + Sultiame 1 Phenytoin Sodium valproate 1 Phenytoin Topiramate 1 Pregabalin Amitriptyline + 1 Cyanocobalamin Pregabalin Sodium valproate 1 Pregabalin + Sodium valproate 1 Goreisan Sodium valproate Aripiprazole + Lorazepam 1 + Promethazine + Risperidone + Brotizolam Sodium valproate Lamotrigine 1 Sodium valproate Levetiracetam 9 Sodium valproate Olanzapine + 1 Flunitrazepam Sodium valproate Phenytoin 2 1 (other adverse reactions) Sodium valproate Zonisamide 5 Sodium valproate + Olanzapine + Etizolam 1 Biperiden + Paliperidone Sodium valproate + Aripiprazole 1 Biperiden + Zopiclone + Paliperidone + Lithium Sodium valproate + Quetiapine + Biperiden 1 Biperiden + Zopiclone (dose escalation) + Paliperidone + Olanzapine + Lorazepam + © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 Flunitrazepam Sodium valproate + Zonisamide 1 1 (cADRs) Clonazepam + Diazepam Sodium valproate + Aripiprazole 1 Clonazepam + Flunitrazepam + Triazolam + Lithium Sodium valproate + Sodium valproate (dose 1 Diazepam + escalation) + Quetiapine Haloperidol + (dose escalation) + Quetiapine + Triazolam + Levomepromazine + Flunitrazepam (dose Chlorpromazine- escalation) promethazine- phenobarbital + Lamotrigine + Risperidone + Trazodone + Brotizolam + Ramelteon + Flunitrazepam Sodium valproate + Topiramate 1 Lamotrigine + Diazepam Sodium valproate + Lamotrigine 1 Levetiracetam Sodium valproate + Phenytoin 1 Levetiracetam Sodium valproate + Levetiracetam (dose 1 Levetiracetam + escalation) Phenytoin + Gabapentin Sodium valproate + Zonisamide (dose 1 Levetiracetam + escalation) Zonisamide + Phenytoin Sodium valproate + Olanzapine 1 Paliperidone + Lorazepam Sodium valproate + Levetiracetam 1 Phenytoin + Diazepam Sodium valproate + Levetiracetam 1 Phenytoin + Phenobarbital Sodium valproate + Olanzapine 1 Quetiapine + Alprazolam + © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/26/2021 Etizolam + Lithium Sodium valproate + Levetiracetam 1 Risperidone Sodium valproate + Aripiprazole + Ramelteon 1 Sertraline + Triazolam + Lomerizine + Lorazepam + Perospirone + Flunitrazepam Sodium valproate + Levetiracetam 1 Topiramate Sodium valproate + Levetiracetam 1 Zonisamide Sulpiride Lorazepam 1 Tramadol- Sodium valproate + 1 acetaminophen Flunitrazepam + Tramadol-acetaminophen (dose escalation) Triazolam + Aripiprazole 1 Lorazepam + Mirtazapine Zonisamide Clonazepam 1 Zonisamide + Sodium valproate 1 Clobazam Zonisamide + Sodium valproate 1 Diazepam + Lorazepam Total 198 One patient who tested positive for HLA-A*31:01 and prescribed carbamazepine is shown in red. As for the drugs of carbamazepine derivatives, oxcarbazepine was approved by Japanese government at November 2016 after we complete the enrolment of this study. Eslicarbazepine is still unavailable in Japan (as of 2017). The reasons for the discontinuation of alternative drugs are shown in the parenthesis. Discontinuation of alternative drugs due to cADRs was occurred in four patients. Among them, two patients who started zonisamide as an alternative drug discontinued zonisamide due to zonisamide-induced cADR. One patient who started levetiracetam and gabapentin as alternative drugs discontinued these drugs due to cADR caused by antibiotics (sulbactam/ampicillin). One patient who started sodium valproate as an alternative drug discontinued this alternative drug by the initial diagnosis of cADR, but this patient was categorized as unlikely after the expert review due to the insufficient information to diagnose either cADR or other skin diseases. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/
Load more

Recommended publications
  • Zonegran, INN-Zonisamide
    SCIENTIFIC DISCUSSION 1. Introduction Many patients (30 to 40% of the overall population with epilepsy) continue to have seizures in spite of receiving antiepileptic drug (AED) treatment. The prevalence of active epilepsy, 5-10/1000, is one of the highest among serious neurological disorders with more than 50 million people affected worldwide. Two peaks of incidence are observed, in early childhood and among elderly people. Some patients will have life-long epilepsy. International classifications, such as the International League Against Epilepsy (ILAE) classification recognise many epileptic diseases or syndromes and each of them can be expressed clinically by one or several seizure groupings. Partial epilepsies (localisation related) are the more frequent, accounting for more than 60% of the epilepsies, and they include most of the difficult-to-treat patients. In terms of seizure types, partial epilepsies include simple partial seizures (without impairment of consciousness), complex partial seizures (with impairment of consciousness and often more disabling) and secondarily generalized tonic-clonic seizures. The symptoms are a function of the localisation of the site of seizure onset in the brain (epileptogenic zone) and of the propagation pathways of the abnormal discharge. Therapeutic management usually follows a staged approach with newly diagnosed patients starting prophylactic treatment with a single drug, and several alternative drugs may be tried in the event of lack of efficacy or poor tolerability. For patients not responding to several attempts of monotherapy, combinations of antiepileptic drugs are generally employed early in the management process. Uncontrolled epilepsy is associated with cognitive deterioration, psychosocial dysfunction, dependent behaviour, restricted lifestyle, poor quality of life and excess mortality, in particular from sudden unexpected death in epilepsy patients (SUDEP).
    [Show full text]
  • Pharmacokinetic Drug–Drug Interactions Among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients
    International Journal of Molecular Sciences Review Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients Marta Kara´zniewicz-Łada 1 , Anna K. Główka 2 , Aniceta A. Mikulska 1 and Franciszek K. Główka 1,* 1 Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 60-781 Pozna´n,Poland; [email protected] (M.K.-Ł.); [email protected] (A.A.M.) 2 Department of Bromatology, Poznan University of Medical Sciences, 60-354 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-(0)61-854-64-37 Abstract: Anti-epileptic drugs (AEDs) are an important group of drugs of several generations, rang- ing from the oldest phenobarbital (1912) to the most recent cenobamate (2019). Cannabidiol (CBD) is increasingly used to treat epilepsy. The outbreak of the SARS-CoV-2 pandemic in 2019 created new challenges in the effective treatment of epilepsy in COVID-19 patients. The purpose of this review is to present data from the last few years on drug–drug interactions among of AEDs, as well as AEDs with other drugs, nutrients and food. Literature data was collected mainly in PubMed, as well as google base. The most important pharmacokinetic parameters of the chosen 29 AEDs, mechanism of action and clinical application, as well as their biotransformation, are presented. We pay a special attention to the new potential interactions of the applied first-generation AEDs (carba- Citation: Kara´zniewicz-Łada,M.; mazepine, oxcarbazepine, phenytoin, phenobarbital and primidone), on decreased concentration Główka, A.K.; Mikulska, A.A.; of some medications (atazanavir and remdesivir), or their compositions (darunavir/cobicistat and Główka, F.K.
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Preventive Report Appendix
    Title Authors Published Journal Volume Issue Pages DOI Final Status Exclusion Reason Nasal sumatriptan is effective in treatment of migraine attacks in children: A Ahonen K.; Hamalainen ML.; Rantala H.; 2004 Neurology 62 6 883-7 10.1212/01.wnl.0000115105.05966.a7 Deemed irrelevant in initial screening Seasonal variation in migraine. Alstadhaug KB.; Salvesen R.; Bekkelund SI. Cephalalgia : an 2005 international journal 25 10 811-6 10.1111/j.1468-2982.2005.01018.x Deemed irrelevant in initial screening Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Amery WK. 1983 Headache 23 2 70-4 10.1111/j.1526-4610.1983.hed2302070 Deemed irrelevant in initial screening Monoamine oxidase inhibitors in the control of migraine. Anthony M.; Lance JW. Proceedings of the 1970 Australian 7 45-7 Deemed irrelevant in initial screening Prostaglandins and prostaglandin receptor antagonism in migraine. Antonova M. 2013 Danish medical 60 5 B4635 Deemed irrelevant in initial screening Divalproex extended-release in adolescent migraine prophylaxis: results of a Apostol G.; Cady RK.; Laforet GA.; Robieson randomized, double-blind, placebo-controlled study. WZ.; Olson E.; Abi-Saab WM.; Saltarelli M. 2008 Headache 48 7 1012-25 10.1111/j.1526-4610.2008.01081.x Deemed irrelevant in initial screening Divalproex sodium extended-release for the prophylaxis of migraine headache in Apostol G.; Lewis DW.; Laforet GA.; adolescents: results of a stand-alone, long-term open-label safety study. Robieson WZ.; Fugate JM.; Abi-Saab WM.; 2009 Headache 49 1 45-53 10.1111/j.1526-4610.2008.01279.x Deemed irrelevant in initial screening Safety and tolerability of divalproex sodium extended-release in the prophylaxis of Apostol G.; Pakalnis A.; Laforet GA.; migraine headaches: results of an open-label extension trial in adolescents.
    [Show full text]
  • Chapter 25 Mechanisms of Action of Antiepileptic Drugs
    Chapter 25 Mechanisms of action of antiepileptic drugs GRAEME J. SILLS Department of Molecular and Clinical Pharmacology, University of Liverpool _________________________________________________________________________ Introduction The serendipitous discovery of the anticonvulsant properties of phenobarbital in 1912 marked the foundation of the modern pharmacotherapy of epilepsy. The subsequent 70 years saw the introduction of phenytoin, ethosuximide, carbamazepine, sodium valproate and a range of benzodiazepines. Collectively, these compounds have come to be regarded as the ‘established’ antiepileptic drugs (AEDs). A concerted period of development of drugs for epilepsy throughout the 1980s and 1990s has resulted (to date) in 16 new agents being licensed as add-on treatment for difficult-to-control adult and/or paediatric epilepsy, with some becoming available as monotherapy for newly diagnosed patients. Together, these have become known as the ‘modern’ AEDs. Throughout this period of unprecedented drug development, there have also been considerable advances in our understanding of how antiepileptic agents exert their effects at the cellular level. AEDs are neither preventive nor curative and are employed solely as a means of controlling symptoms (i.e. suppression of seizures). Recurrent seizure activity is the manifestation of an intermittent and excessive hyperexcitability of the nervous system and, while the pharmacological minutiae of currently marketed AEDs remain to be completely unravelled, these agents essentially redress the balance between neuronal excitation and inhibition. Three major classes of mechanism are recognised: modulation of voltage-gated ion channels; enhancement of gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission; and attenuation of glutamate-mediated excitatory neurotransmission. The principal pharmacological targets of currently available AEDs are highlighted in Table 1 and discussed further below.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]
  • Therapeutic Drug Monitoring of Antiepileptic Drugs by Use of Saliva
    REVIEW ARTICLE Therapeutic Drug Monitoring of Antiepileptic Drugs by Use of Saliva Philip N. Patsalos, FRCPath, PhD*† and Dave J. Berry, FRCPath, PhD† INTRODUCTION Abstract: Blood (serum/plasma) antiepileptic drug (AED) therapeu- Measuring antiepileptic drugs (AEDs) in serum or tic drug monitoring (TDM) has proven to be an invaluable surrogate plasma as an aid to personalizing drug therapy is now a well- marker for individualizing and optimizing the drug management of established practice in the treatment of epilepsy, and guidelines patients with epilepsy. Since 1989, there has been an exponential are published that indicate the particular features of epilepsy and increase in AEDs with 23 currently licensed for clinical use, and the properties of AEDs that make the practice so beneficial.1 recently, there has been renewed and extensive interest in the use of The goal of AED therapeutic drug monitoring (TDM) is to saliva as an alternative matrix for AED TDM. The advantages of saliva ’ fl optimize a patient s clinical outcome by supporting the man- include the fact that for many AEDs it re ects the free (pharmacolog- agement of their medication regimen with the assistance of ically active) concentration in serum; it is readily sampled, can be measured drug concentrations/levels. The reason why TDM sampled repetitively, and sampling is noninvasive; does not require the has emerged as an important adjunct to treatment with the expertise of a phlebotomist; and is preferred by many patients, AEDs arises from the fact that for an individual patient
    [Show full text]
  • Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review
    Current Pain and Headache Reports (2019) 23: 37 https://doi.org/10.1007/s11916-019-0774-0 OTHER PAIN (A KAYE AND N VADIVELU, SECTION EDITORS) Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Omar Viswanath1,2,3 & Ivan Urits4 & Mark R. Jones4 & Jacqueline M. Peck5 & Justin Kochanski6 & Morgan Hasegawa6 & Best Anyama7 & Alan D. Kaye7 Published online: 1 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Neuropathic pain is often debilitating, severely limiting the daily lives of patients who are affected. Typically, neuropathic pain is difficult to manage and, as a result, leads to progression into a chronic condition that is, in many instances, refractory to medical management. Recent Findings Gabapentinoids, belonging to the calcium channel blocking class of drugs, have shown good efficacy in the management of chronic pain and are thus commonly utilized as first-line therapy. Various sodium channel blocking drugs, belonging to the categories of anticonvulsants and local anesthetics, have demonstrated varying degrees of efficacy in the in the treatment of neurogenic pain. Summary Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain. Keywords Neuropathic pain . Chronic pain . Ion Channel blockers . Anticonvulsants . Membrane stabilizers Introduction Neuropathic pain, which is a result of nervous system injury or lives of patients who are affected. Frequently, it is difficult to dysfunction, is often debilitating, severely limiting the daily manage and as a result leads to the progression of a chronic condition that is, in many instances, refractory to medical This article is part of the Topical Collection on Other Pain management.
    [Show full text]
  • Comparison of the Effects of Zonisamide, Ethosuximide and Pregabalin in the Chronic Constriction Injury Induced Neuropathic Pain in Rats
    [Downloaded free from http://www.amhsr.org] Original Article Comparison of the Effects of Zonisamide, Ethosuximide and Pregabalin in the Chronic Constriction Injury Induced Neuropathic Pain in Rats Goyal S, Singla S, Kumar D, Menaria G Department of Pharmacology, Pacific College of Pharmacy, Pacific University, Udaipur, Rajasthan, India Address for correspondence: Dr. Sachin Goyal, Abstract Department of Pharmacology, Background: Evidence has been generated that various anticonvulsant agents provide relief Pacific College of Pharmacy, Pacific University, of several chronic pain syndromes and therefore as an alternative to opioids, nonsteroidal Udaipur ‑ 313 024, Rajasthan, India. anti‑inflammatory, and tricyclic antidepressant drugs in the treatment of neuropathic pain. The E‑mail: [email protected] results of these studies thus raise the question of whether all anticonvulsant drugs or particular mechanistic classes may be efficacious in the treatment of neuropathic pain syndromes. Aim: The aim was to compare the clinically used anticonvulsant drugs which are differ in their mechanism of action in a chronic pain model, the chronic constriction injury, in order to determine if all anticonvulsants or only particular mechanistic classes of anticonvulsants are analgesic. Materials and Methods: The study included zonisamide, ethosuximide and pregabalin. All compounds were anticonvulsant with diverse mechanism of actions. The peripheral neuropathic pain was induced by chronic constriction injury of the sciatic nerve in male Sprague‑Dawley rats. Zonisamide (80 and 40 mg/kg), ethosuximide (300 and 100 mg/kg), pregabalin (50 and 20 mg/kg), and saline was administered intraperitoneally in respective groups in a blinded, randomized manner from postoperative day (POD) 7‑13. Paw withdrawal duration to spontaneous pain, chemical allodynia and mechanical hyperalgesia and paw withdrawal latency to mechanical allodynia and thermal hyperalgesia were tested before drug administration on POD7 and after administration on POD 7, 9, 11 and 13.
    [Show full text]
  • Current Status of Antiepileptic Drugs As Preventive Migraine Therapy Simy K
    Curr Treat Options Neurol (2019) 21: 16 DOI 10.1007/s11940-019-0558-1 Headache (JR Couch, Section Editor) Current Status of Antiepileptic Drugs as Preventive Migraine Therapy Simy K. Parikh, MD Stephen D. Silberstein, MD* Address *Jefferson Headache Center, Thomas Jefferson University, Suite 200, Philadel- phia, PA, 19107, USA Email: [email protected] Published online: 18 March 2019 * Springer Science+Business Media, LLC, part of Springer Nature 2019 This article is part of the Topical Collection on Headache Keywords Migraine I Headache I Preventive therapy I Pharmacology I Antiepileptic drugs I Anticonvulsants Abstract Background Antiepileptic drugs (AEDs) are an important class of agents used in the treatment of migraine, a neurological disorder that imparts significant socioeconomic burden. It is important for neurologists to understand the rationale for AEDs in migraine- preventive treatment, as well as each agent’s efficacy and tolerability profile, in order to best determine clinical care. Purpose of this review This article specifically provides the following: (1) a review of the mechanism of action, efficacy, and tolerability of topiramate and divalproex sodium/ sodium valproate, the most widely used AEDs for migraine prevention, (2) a discussion on emerging evidence regarding the efficacy of zonisamide and levetiracetam, and (3) comments on gabapentin, pregabalin, carbamazepine, oxcarbazepine, and lamotrigine, AEDs which have insufficient evidence for use in migraine prevention. Recent findings The potential role for new extended-release formulations of topiramate in migraine prevention is discussed. Summary There is substantial evidence supporting the use of AEDs in migraine prevention. Specific agents should be chosen based on their efficacy and tolerability profiles.
    [Show full text]
  • Sample Chapter from Martindale
    670 Antimigraine Drugs Antimigraine Drugs periods. Other drugs under investigation include gabapen- 4. Anonymous. Management of medication overuse headache. Drug Ther Bull Cluster headache, p. 670 tin, melatonin, and topiramate.4,9-11,13 2010; 48: 2–6. 5. Bigal ME, Lipton RB. Excessive acute migraine medication use and Medication-overuse headache, p. 670 Paroxysmal hemicrania is a rare variant of cluster migraine progression. Neurology 2008; 71: 1821–8. Migraine, p. 670 headache and differs mainly in the high frequency and 6. British Association for the Study of Headache. Guidelines for all Post-dural puncture headache, p. 671 shorter duration of individual attacks. One of its features, healthcare professionals in the diagnosis and management of migraine, which may be diagnostic, is its invariable response to tension-type, cluster and medication-overuse headache. 3rd edn. Tension-type headache, p. 671 (issued 18th January, 2007; 1st revision, September 2010). Available at: 10 indometacin. http://217.174.249.183/upload/NS_BASH/2010_BASH_Guidelines.pdf 1. Dodick DW, Capobianco DJ. Treatment and management of cluster (accessed 01/12/10) headache. Curr Pain Headache Rep 2001; 5: 83–91. 7. Scottish Intercollegiate Guidelines Network. Diagnosis and management This chapter reviews the management of headache, in 2. Zakrzewska JM. Cluster headache: review of literature. Br J Oral of headache in adults (issued November 2008). Available at: http:// particular migraine and cluster headache, and the drugs Maxillofac Surg 2001; 39: 103–13. www.sign.ac.uk/pdf/sign107.pdf (accessed 26/01/09) Drug Safety used mainly for their treatment. The mechanisms of head 3. Ekbom K, Hardebo JE.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]